dimethylcurcumin

Dimethylcurcumin (ASC-J9) is a synthetic curcumin analogue that acts as a selective androgen receptor (AR) degradation enhancer (ARD enhancer). Unlike traditional anti-androgens that compete with ligands for the AR binding site, ASC-J9 promotes the dissociation of the AR from its coregulators and facilitates its degradation via the ubiquitin-proteasome pathway. This mechanism effectively reduces the total protein levels of both wild-type and mutant androgen receptors, thereby inhibiting AR-mediated transcriptional activity. Developed by AndroScience Corporation, ASC-J9 has been investigated for various androgen-related conditions, including topical applications for acne vulgaris and androgenetic alopecia, and systemic applications for spinal and bulbar muscular atrophy (SBMA) and certain cancers such as renal cell carcinoma and prostate cancer. It has also shown neuroprotective potential in models of amyotrophic lateral sclerosis (ALS) by mitigating oxidative stress and mitochondrial dysfunction associated with TDP-43 mutations.

Other names

DMCDimethoxycurcumin5-hydroxy-1,7-bis(3,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one